Rozalyn Levine Rodwin, MD, MHS
Assistant ProfessorDownloadHi-Res Photo
Cards
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Director, Pediatric HEROS Survivorship Program
About
Titles
Assistant Professor
Director, Pediatric HEROS Survivorship Program
Biography
Dr. Rodwin completed her clinical fellowship in pediatric hematology/oncology at Yale in 2020, and subsequently conducted research in childhood cancer survivorship as a Pediatric Scholar and post-doctoral fellow in the Cancer Prevention and Control T32 Program. She has also served as director of the HEROS Childhood Cancer Survivorship Clinic since 2021. She looks forward to continuing her research aimed at minimizing treatment-related toxicities in childhood cancer survivors and leading the HEROS survivorship program.
Appointments
Pediatric Hematology & Oncology
Assistant ProfessorPrimary
Other Departments & Organizations
- Cancer Prevention and Control
- Janeway Society
- Pediatric Hematology & Oncology
- Pediatric Hematology & Oncology Program
- Pediatric HEROS Survivorship Program
- Pediatrics
- Yale Cancer Center
- Yale Medicine
Education & Training
- MHS
- Yale School of Medicine
- MD
- New York Medical College (2014)
- BS
- Brandeis University
Research
Overview
Medical Research Interests
Survivorship
ORCID
0000-0002-5243-3284
Research at a Glance
Yale Co-Authors
Frequent collaborators of Rozalyn Levine Rodwin's published research.
Publications Timeline
A big-picture view of Rozalyn Levine Rodwin's research output by year.
Research Interests
Research topics Rozalyn Levine Rodwin is interested in exploring.
Xiaomei Ma, PhD
Claudia Auerbach, APRN
Rong Wang, PhD
Lajos Pusztai, MD, DPhil
Lyn Balsamo, PhD
Maryam Lustberg, MD, MPH
15Publications
73Citations
Survivorship
Publications
2024
Patterns of Physical Therapy Referral and Subsequent Attendance Among Childhood Cancer Survivors with Chemotherapy-Induced Peripheral Neuropathy at a Regional Childhood Cancer Survivorship Clinic
Kang L, Kadan-Lottick N, Rotatori J, Kujawski S, Messerschmidt E, Auerbach C, Balsamo L, Lustberg M, Ma X, Rodwin R. Patterns of Physical Therapy Referral and Subsequent Attendance Among Childhood Cancer Survivors with Chemotherapy-Induced Peripheral Neuropathy at a Regional Childhood Cancer Survivorship Clinic. Seminars In Oncology Nursing 2024, 40: 151716. PMID: 39164160, DOI: 10.1016/j.soncn.2024.151716.Peer-Reviewed Original ResearchAltmetricConceptsChildhood cancer survivorsChemotherapy-induced peripheral neuropathyCharacteristics of survivorsPhysical therapyPercentage of adultsPT referralSurvivorship clinicCancer survivorsAttended PTPT attendanceNeighborhood characteristicsChemotherapy-induced peripheral neuropathy symptomsCancer survivorship clinicPhysical therapy referralsHigh school diplomaSurvivor educationCare coordinationOlder survivorsTherapy referralsImprove attendanceMedian percentageCancer diagnosisSchool diplomaPercentage of householdsAttendanceMotor and sensory impairment in survivors of childhood central nervous system (CNS) tumors in the St. Jude Lifetime Cohort (SJLIFE)
Rodwin R, Wang F, Lu L, Li Z, Srivastava D, Phillips N, Khan R, Brinkman T, Krull K, Boop F, Armstrong G, Merchant T, Gajjar A, Robison L, Hudson M, Kadan‐Lottick N, Ness K. Motor and sensory impairment in survivors of childhood central nervous system (CNS) tumors in the St. Jude Lifetime Cohort (SJLIFE). Cancer Medicine 2024, 13: e7422. PMID: 39056576, PMCID: PMC11273544, DOI: 10.1002/cam4.7422.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsSt. Jude Lifetime CohortQuality of lifeChildhood central nervous systemSurvivors of childhood CNS tumorsSensory impairmentChildhood CNS tumorsImpaired physical quality of lifeCentral nervous systemPhysical quality of lifeMotor impairmentCNS tumorsCommon Terminology Criteria for Adverse EventsModified total neuropathy scoreMultivariate modelIn-person evaluationAssociated with older ageClinical assessmentTotal Neuropathy ScoreNervous systemExposure to etoposideModified Common Terminology Criteria for Adverse EventsPrevalence of motorTreating motor impairmentIn-personCraniospinal irradiation
2023
Assessment of proxy‐reported responses as predictors of motor and sensory peripheral neuropathy in children with B‐lymphoblastic leukemia
Rodwin R, DelRocco N, Hibbitts E, Devidas M, Whitley M, Mohrmann C, Schore R, Raetz E, Winick N, Hunger S, Loh M, Hockenberry M, Ma X, Angiolillo A, Ness K, Kairalla J, Kadan‐Lottick N. Assessment of proxy‐reported responses as predictors of motor and sensory peripheral neuropathy in children with B‐lymphoblastic leukemia. Pediatric Blood & Cancer 2023, 70: e30634. PMID: 37592363, PMCID: PMC10552080, DOI: 10.1002/pbc.30634.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsChemotherapy-induced peripheral neuropathyPeripheral neuropathyLymphoblastic leukemiaPediatric Outcomes Data Collection InstrumentPT/OTSensory peripheral neuropathyAcute lymphoblastic leukemiaPredictor of motorProxy-report measuresCommon conditionOccupational therapistsNeuropathyChildrenLeukemiaFunction studiesResponse
2022
A preliminary, prospective study of peripheral neuropathy and cognitive function in patients with breast cancer during taxane therapy
Ibrahim EY, Munshani S, Domenicano I, Rodwin R, Nowak RJ, Pusztai L, Lustberg M, Ehrlich BE. A preliminary, prospective study of peripheral neuropathy and cognitive function in patients with breast cancer during taxane therapy. PLOS ONE 2022, 17: e0275648. PMID: 36206298, PMCID: PMC9543876, DOI: 10.1371/journal.pone.0275648.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsNeurological side effectsSide effectsBreast cancerTaxane exposureProgressive neurological changesTaxane-based chemotherapyNon-interventional studyWeeks of treatmentEnd of treatmentIrreversible side effectsCourse of treatmentQuality of lifeTaxane therapyPeripheral neuropathyProspective studyPeripheral bloodBlood levelsCancer survivalNeuronal viabilityNeurological changesEffective treatmentChemotherapyCognitive impairmentPatientsPotential protein biomarkersHispanic Ethnicity Differences in Birth Characteristics, Maternal Birthplace, and Risk of Early-Onset Hodgkin Lymphoma: A Population-Based Case–Control Study
Graham C, Metayer C, Morimoto LM, Wiemels JL, Siddique A, Di M, Rodwin RL, Kadan-Lottick NS, Ma X, Wang R. Hispanic Ethnicity Differences in Birth Characteristics, Maternal Birthplace, and Risk of Early-Onset Hodgkin Lymphoma: A Population-Based Case–Control Study. Cancer Epidemiology Biomarkers & Prevention 2022, 31: 1788-1795. PMID: 35709749, PMCID: PMC9444874, DOI: 10.1158/1055-9965.epi-22-0335.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsNon-Hispanic whitesHodgkin's lymphomaCase-control studyBirth characteristicsMaternal birthplaceMaternal agePopulation-based case-control studyMultivariable logistic regression modelConfidence intervalsEthnic differencesEarly-onset cancersPotential ethnic differencesForeign-born mothersLogistic regression modelsEthnicity differencesRace/ethnicityYear of birthLymphomaPaternal ageFemale HispanicsHispanic casesMale HispanicsHodgkinAgeRiskPersistence of Chemotherapy-Induced Peripheral Neuropathy Despite Vincristine Reduction in Childhood B-Acute Lymphoblastic Leukemia
Rodwin RL, Kairalla JA, Hibbitts E, Devidas M, Whitley MK, Mohrmann CE, Schore RJ, Raetz E, Winick NJ, Hunger SP, Loh ML, Hockenberry MJ, Angiolillo AL, Ness KK, Kadan-Lottick NS. Persistence of Chemotherapy-Induced Peripheral Neuropathy Despite Vincristine Reduction in Childhood B-Acute Lymphoblastic Leukemia. Journal Of The National Cancer Institute 2022, 114: 1167-1175. PMID: 35552709, PMCID: PMC9360458, DOI: 10.1093/jnci/djac095.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsPhysical Therapy Utilization Among Hospitalized Patients With Pediatric Acute Lymphoblastic Leukemia
Rodwin RL, Ma X, Ness KK, Kadan-Lottick NS, Wang R. Physical Therapy Utilization Among Hospitalized Patients With Pediatric Acute Lymphoblastic Leukemia. JCO Oncology Practice 2022, 18: e1060-e1068. PMID: 35427182, PMCID: PMC9287366, DOI: 10.1200/op.21.00796.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsAcute lymphoblastic leukemiaPediatric acute lymphoblastic leukemiaPhysical therapyPhysical functionLymphoblastic leukemiaNeuromuscular conditionsImpaired physical functionPhysical therapy utilizationPremier Healthcare DatabasePediatric hematologists/oncologistsEarly physical therapyInpatient physical therapyHematologists/oncologistsLong-term healthCohort studyFirst hospitalizationMultivariable analysisTherapy utilizationClinical variablesTeaching hospitalHealthcare databasesPatientsAddress disparitiesHospitalAge 10Biomarkers of Chemotherapy-Induced Peripheral Neuropathy: Current Status and Future Directions
Rodwin RL, Siddiq NZ, Ehrlich BE, Lustberg MB. Biomarkers of Chemotherapy-Induced Peripheral Neuropathy: Current Status and Future Directions. Frontiers In Pain Research 2022, 3: 864910. PMID: 35360655, PMCID: PMC8963873, DOI: 10.3389/fpain.2022.864910.Peer-Reviewed Original ResearchCitationsAltmetricConceptsPeripheral neuropathyChemotherapy-Induced Peripheral NeuropathyTreatment of CIPNMultiple chemotherapeutic agentsQuality of lifeImportant clinical toolCancer survivorsTherapeutic optionsCIPNClinical practicePreventative treatmentPromising biomarkerChemotherapeutic agentsClinical implicationsClinical toolCancer diagnosisBiomarkersNeuropathyStandardized objective measuresPatientsObjective measuresTreatmentRiskChemotherapyComplicationsPatient-reported neurocognitive function in adult survivors of childhood and adolescent osteosarcoma and Ewing sarcoma
Kadan-Lottick NS, Zheng DJ, Wang M, Bishop MW, Srivastava DK, Ross WL, Rodwin RL, Ness KK, Gibson TM, Spunt SL, Okcu MF, Leisenring WM, Robison LL, Armstrong GT, Krull KR. Patient-reported neurocognitive function in adult survivors of childhood and adolescent osteosarcoma and Ewing sarcoma. Journal Of Cancer Survivorship 2022, 17: 1238-1250. PMID: 35059962, PMCID: PMC9300774, DOI: 10.1007/s11764-021-01154-z.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsChronic health conditionsLong-term neurocognitive outcomesNeurocognitive outcomesNeurocognitive difficultiesChildhood osteosarcomaHealth conditionsChildhood Cancer Survivor Study Neurocognitive QuestionnaireAdult survivorsModified Poisson regressionPotential risk factorsOsteosarcoma survivorsSarcoma survivorsNeurocognitive QuestionnaireRisk factorsHigh prevalenceEwing's sarcomaPatient reportsNeurological conditionsRespiratory conditionsTreatment exposureNeurocognitive functionPoisson regressionOsteosarcomaDiagnostic groupsComorbid impairments
2021
Newly identified chemotherapy‐induced peripheral neuropathy in a childhood cancer survivorship clinic
Rodwin RL, Ross WL, Rotatori J, Allen K, Auerbach C, Balsamo LM, Kadan‐Lottick N. Newly identified chemotherapy‐induced peripheral neuropathy in a childhood cancer survivorship clinic. Pediatric Blood & Cancer 2021, 69: e29550. PMID: 34971076, PMCID: PMC8805800, DOI: 10.1002/pbc.29550.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and Concepts
Clinical Trials
Current Trials
A Phase 1/2 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous Clustered Regularly Interspaced Short Palindromic Repeats Gene-edited CD34+ Human Hematopoietic Stem and Progenitor Cells (EDIT-301) in Subjects With Severe Sickle Cell Disease
HIC ID2000032707RoleSub InvestigatorPrimary Completion Date08/01/2025Recruiting ParticipantsA Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma (RELATIVITY-069)
HIC ID2000032969RoleSub InvestigatorPrimary Completion Date07/05/2028Recruiting ParticipantsA Phase 3 Study of Selumetinib (NSC# 748727) or Selumetinib in Combination With Vinblastine for Non-NF1, Non-TSC Patients With Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations
HIC ID2000032978RoleSub InvestigatorPrimary Completion Date12/30/2026Recruiting ParticipantsA Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
HIC ID2000028691RoleSub InvestigatorPrimary Completion Date05/01/2027Recruiting ParticipantsA Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
HIC ID2000028692RoleSub InvestigatorPrimary Completion Date12/31/2026Recruiting Participants
Clinical Care
Overview
Clinical Specialties
Pediatric Hematology & Oncology
Fact Sheets
Acute Lymphoblastic Leukemia (ALL)
Learn More on Yale MedicineNeutropenia
Learn More on Yale MedicineLeukemia in Children
Learn More on Yale MedicineThrombocytopenia
Learn More on Yale Medicine
Yale Medicine News
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileNews
News
- October 14, 2024
Preserving Hope: Fertility Care for Patients with Cancer and Hematological Disorders
- October 09, 2024
Hyundai Hope on Wheels Grant Provides $100K for Childhood Cancer Research at Yale
- September 25, 2023
Rozalyn Rodwin, MD, in honor of Childhood Cancer Awareness Month
- August 17, 2023
Rozalyn Levine Rodwin, MD, Awarded $100,000 Grant to Treat Survivors of Childhood Cancer
Get In Touch
Contacts
Appointment Number
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.